Profile data is unavailable for this security.
About the company
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
- Revenue in USD (TTM)58.42m
- Net income in USD2.49m
- Incorporated1985
- Employees213.00
- LocationChampions Oncology IncOne University Plaza,, Suite 307HACKENSACK 07601United StatesUSA
- Phone+1 (201) 808-8400
- Fax+1 (302) 636-5454
- Websitehttps://championsoncology.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precision BioSciences Inc | 698.00k | -83.60m | 81.74m | 67.00 | -- | 2.59 | -- | 117.11 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Incannex Healthcare Inc | 12.00k | -47.87m | 86.56m | 12.00 | -- | 1.13 | -- | 7,213.03 | -0.9375 | -0.9375 | 0.0001 | 0.2215 | 0.0003 | -- | 0.0015 | 1,000.00 | -101.03 | -155.80 | -114.13 | -186.20 | -- | -- | -398,933.30 | -6,230.96 | -- | -43.84 | 0.00 | -- | 616.67 | -31.02 | -154.00 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -27.99m | 88.25m | 25.00 | -- | 2.42 | -- | -- | -0.4816 | -0.4816 | 0.00 | 0.4138 | 0.00 | -- | -- | 0.00 | -78.86 | -59.00 | -108.44 | -75.05 | -- | -- | -- | -- | -- | -3,450.08 | 0.00 | -- | -- | -- | -31.73 | -- | -51.16 | -- |
| Oncolytics Biotech Inc | 0.00 | -25.73m | 90.02m | 29.00 | -- | 1,033.64 | -- | -- | -0.2861 | -0.2861 | 0.00 | 0.0008 | 0.00 | -- | -- | -- | -179.40 | -75.50 | -293.88 | -87.03 | -- | -- | -- | -- | -- | -- | 0.879 | -- | -- | -- | -14.26 | -- | 85.40 | -- |
| Equillium Inc | 4.39m | -24.42m | 90.12m | 35.00 | -- | 2.90 | -- | 20.52 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
| Champions Oncology Inc | 58.42m | 2.49m | 90.68m | 213.00 | 39.18 | 21.75 | 22.80 | 1.55 | 0.1667 | 0.1667 | 4.14 | 0.3003 | 2.11 | -- | 5.31 | 274,291.10 | 8.78 | -4.67 | 33.91 | -11.66 | 50.11 | 47.28 | 4.16 | -2.79 | -- | -- | 0.0327 | -- | 13.54 | 12.13 | 164.61 | -- | -29.41 | -- |
| eXoZymes Inc | 0.00 | -8.34m | 91.14m | 31.00 | -- | 16.93 | -- | -- | -1.76 | -1.76 | 0.00 | 0.6408 | 0.00 | -- | -- | 0.00 | -147.87 | -- | -393.50 | -- | -- | -- | -- | -- | -- | -- | 0.0217 | -- | -- | -- | -187.55 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -106.03m | 91.30m | 30.00 | -- | 1.12 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| Anixa Biosciences Inc | 0.00 | -10.93m | 91.79m | 4.00 | -- | 5.99 | -- | -- | -0.3369 | -0.3369 | 0.00 | 0.4593 | 0.00 | -- | -- | 0.00 | -58.55 | -47.85 | -62.09 | -49.81 | -- | -- | -- | -8,381.30 | -- | -- | 0.00 | -- | -- | -- | 12.96 | -- | -- | -- |
| Dogwood Therapeutics Inc | 0.00 | -39.98m | 94.24m | 12.00 | -- | -- | -- | -- | -24.92 | -24.92 | 0.00 | 33.75 | 0.00 | -- | -- | 0.00 | -81.05 | -52.48 | -84.58 | -55.93 | -- | -- | -- | -- | -- | -178.51 | 0.00 | -- | -- | -- | -142.90 | -- | -- | -- |
| Artiva Biotherapeutics Inc | 0.00 | -79.19m | 94.99m | 106.00 | -- | 0.7351 | -- | -- | -3.25 | -3.25 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -42.29 | -44.57 | -45.24 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0006 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Pyxis Oncology Inc | 2.82m | -97.09m | 95.89m | 44.00 | -- | 1.39 | -- | 34.00 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | -24.76m | 97.99m | -- | -- | 2.07 | -- | -- | -0.3400 | -0.3400 | 0.00 | 0.5372 | 0.00 | -- | -- | -- | -26.72 | -- | -48.02 | -- | -- | -- | -- | -- | 0.1062 | -129.48 | 0.0781 | -- | -- | -- | -17.08 | -- | -- | -- |
| Cardiff Oncology Inc | 501.00k | -50.45m | 99.69m | 32.00 | -- | 2.04 | -- | 198.99 | -0.7976 | -0.7976 | 0.0079 | 0.7272 | 0.0079 | -- | 1.15 | 15,656.25 | -79.61 | -32.23 | -101.41 | -34.83 | -- | -- | -10,064.27 | -7,588.71 | -- | -- | 0.00 | -- | 39.96 | 22.80 | -9.62 | -- | 3.42 | -- |
| Shanrong Biotechnology Corp | 1.32m | -5.08m | 100.05m | 3.00 | -- | -- | -- | 75.52 | -15.40 | -15.40 | 4.10 | -11.40 | 4.45 | -- | 11.81 | 441,576.70 | -1,705.30 | -- | -- | -- | -- | -- | -383.32 | -- | 0.0315 | -16.22 | -- | -- | 91.44 | -- | -86.62 | -- | -- | -- |
| Agenus Inc | 106.83m | -35.38m | 100.11m | 316.00 | -- | -- | -- | 0.9371 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
Data as of Feb 06 2026. Currency figures normalised to Champions Oncology Inc's reporting currency: US Dollar USD
15.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| West Elk Capital LLCas of 30 Sep 2024 | 882.58k | 6.36% |
| Tocqueville Asset Management LPas of 30 Sep 2025 | 319.67k | 2.30% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 299.52k | 2.16% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2025 | 189.60k | 1.37% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 167.26k | 1.21% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 118.76k | 0.86% |
| Geode Capital Management LLCas of 30 Sep 2025 | 74.41k | 0.54% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 36.18k | 0.26% |
| Hightower Advisors LLCas of 30 Sep 2025 | 35.16k | 0.25% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 32.99k | 0.24% |
More ▼
Data from 19 Feb 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
